Health Policy, Health Economics, Outcomes Research, Medications, Older Adult Care, Real-World Data, Long-Term Care, Pharmacy, Pharmacist-directed care
Inaugural Fellow, University of Washington/AbbVie Health Economics and Outcomes Research Fellowship (former UW/Allergan Global Health Economics and Outcomes Research Fellowship), 2007-2009.
-National Academy of Medicine (former Institute of Medicine) Anniversary Fellow, 2016-2018
-National Academy of Medicine Emerging Leader in Health and Medicine Scholar, National Academy of Medicine (2018- present)
-University of Washington Distinguished Alumnae in Pharmaceutical Science and Research award (2018).
-University of Washington School of Pharmacy "Alumni Legend", School of Pharmacy 125th Anniversary Celebration (2019)
-Distinguished Fellow, non-profit Get the Medications Right Institute (2019 - present)
-NIH Loan Repayment Program Awardee 2016-2018
-PhRMA Value Assessment Challenge Paper Award 2020
Professor Watanabe is a pharmacist, health economist, and outcomes researcher. He serves as a Member of the National Academies of Sciences, Engineering, and Medicine (NASEM) Forum on Drug, Discovery, Development, and Translation. In this capacity, Professor Watanabe has been involved in methods development for pragmatic clinical trials through the FDA-sponsored Real-World Evidence Series and serves on the steering committee for the Drug Research Development in Older Adults Workshop. Professor Watanabe applies real-world data to develop policy solutions to improve patient care, bolster population-health, and reduce medical costs. He was a contributor to the NASEM report Making Medicines Affordable: a National Imperative. His research on health implications of non-optimized medication regimens has been cited in multiple successful state legislative efforts to bolster patient-centered care and medication management, and he has testified before the California Senate Health Panel regarding value of comprehensive medication management services to bolster the health and wellness of Californians enrolled in Medicaid. He is a consultant to the California Health Benefits Review Program of the California State Legislature and served on the Advisory Group on Pain Assessment and Management in Long-Term Care Settings for the Joint Commissions. He is currently appointed to the NASEM committee on Implications of Discarded Weight-Based Medications mandated funded by the Centers for Medicare and Medicaid Services. Dr. Watanabe was the first recipient of the University of Washington/Allergan Global Health Economics and Outcomes Research Fellowship. He received his BS from the University of Washington, his PharmD from the University of Southern California, and his MS and PhD from the University of Washington Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. He is past recipient of the University of Washington Distinguished Alumnae in Pharmaceutical Science and Research award. He is a past National Academy of Medicine (NAM) Anniversary Fellow in Pharmacy sponsored by the American Association of Colleges of Pharmacy and the American College of Clinical Pharmacy. He currently serves as a Scholar in the NAM Emerging Leaders in Health and Medicine Program and serves as a Distinguished Fellow of the Get the Medications Right Institute. He is a Board-Certified Geriatric Pharmacist (BCGP).
Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. https://doi.org/10.17226/24946. National Academy of Sciences, Engineering, and Medicine (ad hoc), Committee on patient access to affordable and effective therapies.
Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality. Ann Pharmacother. 2018 Sep;52(9):829-837. doi:10.1177/1060028018765159. Epub 2018 Mar 26. PubMed PMID: 29577766.
Watanabe JH, Chau DL, Hirsch JD. Federal and individual spending on the 10 costliest medications in Medicare Part D from 2011 to 2015. J Am Geriatr Soc. 2018 Aug;66(8):1621-1624. doi: 10.1111/jgs.15443. Epub 2018 Jul 4. PubMed PMID:29972589.
Nguyen HK, Humber D, Checkoway H, Blanchard D, Watanabe JH. Anticoagulant use in high stroke-risk patients with nonvalvular atrial fibrillation. Consult Pharm 2018 Sep 1;33(9):521-530. doi: 10.4140/TCP.n.2018.521. PubMed PMID: 30185292.
Watanabe JH. Considerations for propensity score digit match selection and confounder balance in a observational health database analysis. Sage Research Methods Cases.
Davidson JE, Marshall MF, Watanabe JH. Policy impact: when policy fails. Nursing Forum. In-Press. Davidson JE, Marshall MF, Watanabe JH. Policy impact: When policy fails. NursForum. 2019 Aug 20. doi: 10.1111/nuf.12380. [Epub ahead of print] PubMed PMID:31432541.
Luli AJ, Bounthavong M, Watanabe JH. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. J Am Pharm Assoc (2003). 2019 Dec 27. pii: S1544-3191(19)30497-2. doi:10.1016/j.japh.2019.10.014. [Epub ahead of print] PubMed PMID: 31889651.
Watanabe JH. Medication use, falls, and fall-related worry in older adults in the United States. Consult Pharm. 2016 Jul;31(7):385-93. doi: 10.4140/TCP.n.2016.385. PubMed PMID: 27412315.
Watanabe JH and Ney JP. Association of increased emergency rooms costs for patients without access to necessary medications. Res Social Adm Pharm. 2014 Oct 31. pii: S1551-7411(14)00337-4. doi: 10.1016/j.sapharm.2014.10.007. [Epub ahead of print] PubMed PMID: 25487421.
Bounthavong M, Watanabe JH, Sullivan K. Approach to addressing missing data for electronic medical records and pharmacy claims data research. Pharmacotherapy. 2015 Apr;35(4):380-7. doi: 10.1002/phar.1569. PubMed PMID: 25884526.
Watanabe JH and Yang J. Hospitalization and combined use of opioids, benzodiazepines, and muscle relaxants in the United States. Hospital Pharmacy. 2019 Dec 18; https://doi.org/10.1177/0018578719894702.
Sepassi A and Watanabe JH. Emergency department visits for psychotropic-related adverse drug events in older adults with Alzheimer’s Disease, 2013-2014. Ann Pharmacother. 2019 Jul 25:1060028019866927. doi: 10.1177/1060028019866927. [Epub ahead of print] PubMed PMID: 31342766.
Watanabe JH, Hazlet TK, Sullivan SD. Generic medication utilization policies in the United States and Medicaid sustainability. J Pharm Health Serv Res. 2015. 6: 3–10. doi: 10.1111/jphs.12084
Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. Definition and classification of generics across the world. Appl Health Econ Health Policy. Appl Health Econ Health Policy. 2015 Aug;13 Suppl 1:S5-11. doi: 10.1007/s40258-014-0146-1. PubMed PMID: 26091708; PubMed Central PMCID: PMC4519628.
Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin. 2013 Mar;29(3):175-80. doi: 10.1185/03007995.2013.766164. Epub 2013 Feb 1. PubMed PMID: 23320610.
Kazerooni R, Watanabe JH. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population. J Manag Care Spec Pharm. 2021 Jan 29:1-9. doi: 10.18553/jmcp.2021.20346. Epub ahead of print. PMID: 33511895.
Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014 Jan;20(1):43-50. PubMed PMID: 24372459.
Watanabe JH. Examining the pharmacist labor supply in the United States: Increasing medication use, aging society, and evolution of pharmacy practice. Pharmacy (Basel). 2019 Sep 19;7(3). pii: E137. doi: 10.3390/pharmacy7030137. PubMed PMID: 31546891.
Tam SHY, Hirsch JD, Watanabe JH. Medication regimen complexity in long-term care facilities and adverse drug events-related hospitalizations. Consult Pharm. 2017 May 1;32(5):281-284. doi: 10.4140/TCP.n.2017.281. PubMed PMID: 28483008